Develops oral drugs for metabolic dysfunction-associated steatohepatitis.
Dec 2024Revenue €9.20M/yrExpenses €107M/yr
No trendCash runway ≈ 1.1 years from Dec 2024
Figures by year
When will Inventiva be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was €9.20M and expenses €107M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | €9.20M | €107M | −€97.6M |
| Dec 2023 | €17.5M | €120M | −€103M |
| Dec 2022 | €12.2M | €69.3M | −€57.1M |
| Dec 2021 | €4.19M | €56.3M | −€52.1M |
| Dec 2020 | €372K | €30.1M | −€29.7M |
| Dec 2019 | €7.00M | €37.3M | −€30.3M |
| Dec 2018 | €3.20M | €36.1M | −€32.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.